First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Shaan Dudani(William Osler Health System), Daniel Yick Chin Heng(University of Calgary), Camillo Porta(University of Pavia), Aaron R. Hansen(Princess Margaret Cancer Centre), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Sumanta K. Pal(City of Hope), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Jeffrey Graham(University of Calgary), Marco Iafolla(University of Alberta), Lori Wood(Dalhousie University), Chiyuan A. Zhang(Columbia University Irving Medical Center), Christian Kollmannsberger(BC Cancer Agency), Takeshi Yuasa(Japanese Foundation For Cancer Research), Nazlı Dizman(City Of Hope National Medical Center), Flora Yan(Temple University), Ulka N. Vaishampayan(University of Michigan), Elizabeth Liow(Peter MacCallum Cancer Centre)
Cited by 5
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k